PureTech Health (LON:PRTC) Trading Up 14.2% - Still a Buy?

Key Points

• PureTech Health's stock experienced a significant rise of 14.2%, closing at GBX 121.50 ($1.64) with a high of GBX 123.80 during trading.
• The company's trading volume surged by 1,053%, with approximately 9 million shares changing hands compared to an average of around 781,000 shares.
• Insider Bharatt Chowrira bought 167,739 shares at an average price of GBX 1 per share, indicating confidence in the company's prospects, with insiders owning 13.13% of the stock.

PureTech Health plc (LON:PRTC - Get Free Report) was up 14.2% during trading on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares traded hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 14.2%

The firm has a market capitalization of £293.65 million, a PE ratio of 714.71 and a beta of 1.02. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The business's fifty day moving average price is GBX 129.46 and its 200 day moving average price is GBX 129.76.

Insider Activity at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction dated Thursday, July 3rd. The stock was acquired at an average cost of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is currently owned by company insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.